Valuation
- Market cap
- 101,553,000
- Revenue TTM
- $1,550,000
- Net income TTM
- $-63,060,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -4,068.39%
- Debt to equity
- 0.00
Trading
- Volume
- 769,500
- Avg volume
- 1,538,770
- Day's range
- $0.79 – $0.83
- Shares out
- 124,498,000
- Stochastic %K
- 33%
- Beta
- 1.01
- Analysts
- Strong Sell
- Price target
- $5.86
Company profile
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the ind...
Show more
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 514 336 0444
- Website
- https://www.milestonepharma.com
- Address
- 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Canada
Latest news
No headlines yet.
